dc.creator | Valdés Delgado, Teresa | es |
dc.creator | Guerra Veloz, María Fernanda | es |
dc.creator | Castro Laria, Luisa | es |
dc.creator | Maldonado Pérez, Belén | es |
dc.creator | Perea Amarillo, Raúl | es |
dc.creator | Merino Bohórquez, Vicente | es |
dc.creator | Sáez, Antonia | es |
dc.creator | Caunedo Álvarez, Ángel | es |
dc.creator | Argüelles Arias, Federico | es |
dc.date.accessioned | 2024-05-09T14:11:50Z | |
dc.date.available | 2024-05-09T14:11:50Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Valdés Delgado, T., Guerra Veloz, M.F., Castro Laria, L., Maldonado Pérez, B., Perea Amarillo, R., Merino Bohórquez, V.,...,Argüelles Arias, F. (2020). Cut-off ranges of infliximab serum levels in Crohn’s disease in the clinical practice. Revista Española de Enfermedades Digestivas, 112 (10), 756-761. https://doi.org/10.17235/reed.2020.6539/2019. | |
dc.identifier.issn | 1130-0108 | es |
dc.identifier.issn | 2340-4167 | es |
dc.identifier.uri | https://hdl.handle.net/11441/158012 | |
dc.description.abstract | Introduction: between 30 % and 40 % of patients treated
with infliximab lose response during maintenance. Ther apeutic drug monitoring could be used to optimize man agement in these situations. However, infliximab serum
levels are not well defined. The aim of this study was to
determine the cut-off range of infliximab serum levels
in Crohn’s disease patients in remission in the clinical
practice.
Methods: an observational retrospective study was per formed from 2016 to 2017. Patients were included with
established Crohn’s disease, who had been on a mainte nance dose schedule of infliximab. Infliximab levels and
antibodies to infliximab were measured at least twice in
all patients, after induction and after six months of treat ment. Clinical remission was defined as ≤ 4 using the Har vey-Bradshaw index. Cluster analysis was used to analyze
the results.
Results: one hundred and five Crohn’s disease patients
were included in the study; 57.1 % were male with a mean
age of 39 years (SD ± 12.9). The median (range) time of the
disease was eleven years (7-15) and the median (range)
time of follow-up was 32 months (22-38). Patients who
achieved remission had infliximab serum levels between
4.26-8.26 ug/ml versus 0.06-1.43 ug/ml in patients who
did not achieve remission after induction. Infliximab
serum levels were 2.84-7.75 ug/ml and 0.05-2.69 ug/ml
in patients who achieved remission versus those who
did not achieve remission after six months of treatment.
Overall, 4.26-8.26 ug/ml was found to be the best cut-off
range for remission.
Conclusions: in our clinical practice, serum levels of inflix imab in Crohn’s disease patients should be higher than 4
ug/ml to achieve clinical remission. | es |
dc.format | application/pdf | es |
dc.format.extent | 6 p. | es |
dc.language.iso | eng | es |
dc.publisher | Aran Ediciones S.A. | es |
dc.relation.ispartof | Revista Española de Enfermedades Digestivas, 112 (10), 756-761. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Infliximab levels | es |
dc.subject | Infliximab antibodies | es |
dc.subject | Thera peutic drug monitoring | es |
dc.title | Cut-off ranges of infliximab serum levels in Crohn’s disease in the clinical practice | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Farmacología | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.reed.es/ArticuloFicha.aspx?id=4381&hst=0&idR=89&tp=1 | es |
dc.identifier.doi | 10.17235/reed.2020.6539/2019 | es |
dc.journaltitle | Revista Española de Enfermedades Digestivas | es |
dc.publication.volumen | 112 | es |
dc.publication.issue | 10 | es |
dc.publication.initialPage | 756 | es |
dc.publication.endPage | 761 | es |